Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 7Plasma cell 3Sarcoma 2Myeloid 2Classical hematology 2Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Recurrence 1Esophageal Neoplasms 1

Interventions

Oxaliplatin 197Bevacizumab 162Fluorouracil 155Capecitabine 137Gemcitabine 133Leucovorin 112pembrolizumab 99Cisplatin 93Drug Therapy 89Irinotecan 81Radiotherapy 73sintilimab 70durvalumab 65130-nm albumin-bound paclitaxel 65Paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 59tislelizumab 58Nivolumab 55Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 48Biopsy 46Surgical Procedures, Operative 40Taxes 38Albumin-Bound Paclitaxel 38Immune Checkpoint Inhibitors 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × pegylated granulocyte colony-stimulating factor × Gastrointestinal × Clear all
NCT03731442 2018-12-12

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

ChineseAMS

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡